[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586811":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":53,"collaborators":56,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":19,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":19,"enrollmentInfo":69,"targetDuration":19,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":81,"overallStatus":37,"whyStopped":19,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Trustees of Dartmouth College","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Therabot-CALM","EXPERIMENTAL","Participants will engage in three one-hour interviews and a 4-week clinical trial where they may interact with Therabot-CALM as much or as little as they want.",[13],"Device: Therabot-CALM",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DEVICE","Therabot is a generative-AI-driven mobile app designed to provide mental health treatment. The feasibility of Therabot-CALM, an adapted Therabot application, is being tested for the future use of treating co-occurring substance use disorders and anxiety and\u002For depression. The primary purpose of this study is application feasibility.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Nicholas C Jacobson, Ph.D.","Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Michael V Heinz, MD","CONTACT","(603) 277-9110","michael.v.heinz@hitchcock.org",{"name":32,"role":28,"phone":19,"phoneExt":19,"email":33},"Amanda C Collins, Ph.D.","Amanda.C.Collins@dartmouth.edu",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"46 Centerra Parkway, Suite 300, Office #333S","RECRUITING","Lebanon","New Hampshire","03766","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-72.25176,43.64229,{"lat":47,"lon":46},[50],{"name":22,"role":28,"phone":51,"phoneExt":19,"email":52},"8148630115","Nicholas.C.Jacobson@dartmouth.edu",{"type":24,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Nicholas Jacobson","Associate Professor",[57],{"name":58,"class":59},"National Institute on Drug Abuse (NIDA)","NIH","100586811","phase-1-use-of-a-generative-ai-gen-ai-chatbot-for-anxiety-and-depression-among-persons-with-cannabis-use-100586811",false,"NCT06920238","Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use","A Phase I Single-Arm Trial to Test the Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use Disorder (CUD)","Inclusion Criteria:\n\n* Is 18 years or older.\n* Meet criteria for current CUD (CUDIT-R\\>=12) and MDD (PHQ-9\\>=10), and\u002For GAD (GAD-7\\>=10).\n* Have reliable access to the internet and a compatible device for Therabot-CALM.\n* Have willingness and capacity to provide informed consent and commit to participating in all assessments and interventions during the study.\n* Attend the first interview.\n\nExclusion Criteria:\n\n* Moderate to High risk of STBs as determined by the C-SSRS or baseline questionnaires.\n* Current psychosis (as determined by brief psychosis screen).\n* Current participation in another digital mental health intervention.","ALL","18 Years",{"count":70,"type":71},15,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","The goal of this clinical trial is to learn if Therabot-CALM (Cannabis, Anxiety, Low Mood) has acceptability among users and could work to improve the symptoms of persons with cannabis use disorder and anxiety and\u002For depression. The main question it aims to answer is:\n\nWhat is the usability, feasibility, and acceptability of Therabot-CALM in persons with Cannabis Use Disorder and Anxiety and\u002For Depression?\n\nParticipants will\n\n* Take a screening questionnaire\n* Participate in two virtual 1-hour interviews to provide feedback on app design and suggest features.\n* Engage with Therabot-CALM in a 4-week clinical trial and provide feedback on their app experience in a third virtual interview",[77,78,79,80],"Cannabis Use Disorder","Anxiety","Depression, Anxiety","Depression - Major Depressive Disorder",[82,83,84,85,9,77,78,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105],"Artifical Intelligence","Generative AI","Generative Artificial Intelligence","Therabot","Depression","Chatbot","Cannabis Use","Drug Abuse","Drug Use","Drug Use Disorder","Interview","Screening","Application","REDCap","post-intervention measures","System Usability Scale","Treatment Acceptability and Adherence Scale","Cannabis Use Disorders Identification Test - Revised","Cannabis Use Disorders Identification Test","Quantity of Cannabis Use Inventory","Patient Health Questionnaire for depression","generalized anxiety disorder screener","DSM-5","Zoom","2025-09-05",{"date":108,"type":109},"2025-09-08","ACTUAL",{"date":111,"type":109},"2025-04-13",{"date":113,"type":71},"2025-12",{"name":5,"class":6},1]